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Abstract The addition of adjuvant trastuzumab therapy for
1 year to standard chemotherapy significantly improved
disease-free survival and overall survival versus chemotherapy
alone in a number of pivotal early breast cancer studies. Here
we review long-term follow-up data on the efficacy, cardiac
safety, and general safety of trastuzumab in these pivotal stud-
ies. We also evaluate ongoing phase II/III adjuvant trials with
newer HER2-targeted agents and the efficacy and safety of the
recently developed subcutaneous (SC) formulation of
trastuzumab in early breast cancer. Long-term follow-up data
confirm the significant survival benefit afforded by the addition
of trastuzumab to chemotherapy in patients with HER2-
positive disease, with an acceptable safety profile. Long-term
cardiac safety data suggest that the incidence of cardiac adverse
events is maintained at a relatively low level with continued
follow-up. At this present time, 1 year of trastuzumab treatment
remains the standard of care in HER2-positive early breast
cancer. Future adjuvant trastuzumab treatment strategies should
focus on reducing cardiotoxicity, particularly in elderly pa-
tients, by identifying potential predictive biomarkers of cardiac
dysfunction. Clinicians must also decide whether to omit
trastuzumab in women who would achieve little benefit from
treatment to avoid cardiotoxicity.
Key Points
We reviewed long-term efficacy and safety data from a 
number of pivotal studies that reported significant 
survival benefits with the addition of 1 year of adjuvant 
trastuzumab therapy to standard chemotherapy in 
patients with HER2-positive early breast cancer.
The significant survival benefits seen with trastuzumab 
were maintained with long-term follow-up, with an 
acceptable safety profile including a relatively low level 
of cardiac adverse events.
Reducing cardiotoxicity should be a key factor of future
adjuvant trastuzumab treatment strategies, particularly 
in the elderly and in those who would achieve little 
benefit from treatment. 
1 Introduction
Thirty years have passed since the discovery of the neu onco-
gene and subsequent identification of the human epidermal
growth factor receptor 2 (HER2) transmembrane receptor ty-
rosine kinase that it encodes [1, 2]. Overexpression of HER2
was quickly recognized to confer poor prognosis in women
with metastatic breast cancer [3]. This discovery led rapidly to
the development of trastuzumab (Herceptin®, Genentech,
South San Francisco, CA, USA), a humanized HER2-
targeting monoclonal antibody, and a clinical trials program
ultimately leading to a license for the treatment of metastatic
breast cancer overexpressing HER2 [4–6].
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The success of trastuzumab in the metastatic setting gener-
ated much optimism for this agent in the adjuvant setting.
Approximately 90 % of breast cancer is diagnosed in the early
stages of the disease, and it is estimated that HER2-positive
tumors account for 15−20 % of invasive breast cancers
[7]. Prior to the development of trastuzumab, women
with HER2-positive disease faced a worse prognosis
than those with HER2-negative disease, including
shorter time to relapse, a higher incidence of metastasis,
and reduced survival [8].
Subsequently, a number of early breast cancer studies
showed that the addition of adjuvant trastuzumab therapy
for 1 year to standard chemotherapy significantly im-
proved disease-free survival (DFS) and overall survival
(OS) versus chemotherapy alone, with an acceptable safe-
ty profile [9–13]. Here we review long-term follow-up
data on the efficacy and safety of trastuzumab in these
pivotal studies. We also evaluate ongoing adjuvant trials
with newer HER2-targeted agents in early breast cancer,
as well as the recently developed subcutaneous (SC) for-
mulation of trastuzumab.
2 Adjuvant Trastuzumab: Long-term Efficacy Data
Long-term follow-up data from a number of studies in the
early breast cancer setting confirm the significant survival
benefit afforded by the addition of trastuzumab to chemother-
apy in patients with HER2-positive disease.
2.1 HERA Study
The randomized, phase III HERA study (HERceptin
Adjuvant) assessed the efficacy of trastuzumab in the ad-
juvant setting, as well as testing two durations of
trastuzumab treatment. The study compared 1 or 2 years
of trastuzumab with observation alone in 5102 women
with HER2-positive early-stage invasive breast cancer
who had completed at least four cycles of neoadjuvant or
adjuvant chemotherapy.
In patients receiving trastuzumab for 1 year, 127 DFS
events were reported versus 220 in the observation group
(hazard ratio [HR] 0.54, 95 % confidence interval
[CI] 0.43−0.67; p<0.0001) after amedian follow-up of 1 year,
corresponding to an 8.4 % absolute benefit in 2-year DFS rate
(85.8 % vs 77.4 %, respectively) [9]. With further maturity, this
DFS advantage was maintained (HR 0.76, 95 % CI 0.67−0.86;
p<0.0001) and resulted in a significant OS benefit (HR 0.76,
95 % CI 0.65−0.88; p=0.0005) after a median follow-up of
8 years and crossover of 884 patients (52 %) from observation
to trastuzumab (Fig. 1) [14].
Comparison of the efficacy of trastuzumab in patients re-
ceiving 2 years versus 1 year of treatment was assessed in a
landmark analysis including 3105 patients who were disease-
free 12 months after randomization. At the clinical cutoff date
for this analysis, 367 DFS events were recorded in both the
2-year trastuzumab group and the 1-year trastuzumab group,
with no significant between-group DFS difference noted (HR
0.99, 95 % CI 0.85−1.14; p=0.86) [14]. Thus, 2 years of
trastuzumab treatment following adjuvant chemotherapy was
not more effective than 1 year of treatment. Ten-year follow-up
data from HERAwill be published in the coming months.
2.2 NSABP B-31 and NCCTG N9831 Combined Data
Two studies of adjuvant chemotherapy with or without
trastuzumab in women with surgically removed HER2-
positive breast cancer were sponsored by The National
Cancer Institute. The NSABP B-31 trial (National Surgical
Adjuvant Breast and Bowel Project B-31) compared doxoru-
bicin and cyclophosphamide (AC) followed by paclitaxel ev-
ery 3 weeks (group 1) with AC followed by 1 year of concur-
rent trastuzumab and 12 weeks of paclitaxel (group 2). The
NCCTG N9831 trial (North Central Cancer Treatment Group
N9831) compared AC followed by weekly paclitaxel
(group A), with AC followed by weekly paclitaxel then 1 year
of trastuzumab (group B), and AC followed by 1 year of
concurrent trastuzumab and 12 weeks of paclitaxel (group C).
A combined analysis of the two studies after a median
follow-up of 2 years compared data from 1679 patients in
groups 1 and A (control groups) with data from 1672 patients
in groups 2 and C (trastuzumab groups) [10]. The sequential
group B of the N9831 study was excluded from this analysis.
Trastuzumab combined with adjuvant chemotherapy reduced
the risk of a DFS event (HR 0.48, 95 % CI 0.39−0.59;
p<0.0001) and OS event versus chemotherapy alone (HR
0.67, 95 % CI 0.48−0.93; p=0.015) [10]. These survival ben-
efits for the trastuzumab group versus the chemotherapy group
were maintained after a median follow-up of 4 years, with a
relative reduction in DFS event rate of 48% (HR 0.52, 95%CI
0.45−0.60; p<0.001) and a relative reduction in death rate of
39 % (HR 0.61, 95 % CI 0.50−0.75; p<0.001) [15].
Updated analyses after a median follow-up of 8.4 years,
including 2018 patients in the control group and 2028 patients
in the trastuzumab group, confirmed a substantial survival
benefit with the addition of trastuzumab to adjuvant chemo-
therapy. There was a 37 % relative improvement in OS versus
the chemotherapy group (HR 0.63, 95 % CI 0.54−0.73;
p < 0.001) and an increase in the 10-year OS rate from
75.2 % to 84.0 % [16]. Patients treated with trastuzumab plus
chemotherapy also achieved a 40% improvement in DFS (HR
0.60, 95 % CI 0.53−0.68; p<0.001) versus chemotherapy
alone, and an increase in the 10-year DFS rate from 62.2 %
to 73.7 % (Fig. 2). All patient subgroups defined by age,
hormone receptor status, and tumor size derived similar
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benefits from the addition of trastuzumab to adjuvant chemo-
therapy [16].
NCCTG N9831 was the only study to directly compare
sequential trastuzumab after completion of anthracycline-
based chemotherapy with delivery concomitant with the
taxane portion of chemotherapy. After a median of
3.9 years of follow-up, a strong trend towards increased
5-year DFS was noted with concurrent trastuzumab and
paclitaxel relative to sequential administration (HR 0.77,
99.9 % CI 0.53−1.11; p=0.0216), but the p value did
not cross the prespecified O’Brien–Fleming boundary for
the interim analysis [17].
Fig. 2 Combined data analysis of aOS and bDFS after a median follow-
up of 8.4 years in the NSABP B-31 and NCCTGN9831 studies [16]. AC
→ T doxorubicin and cyclophosphamide followed by paclitaxel, AC→
TH doxorubicin and cyclophosphamide followed by paclitaxel and
trastuzumab, CI confidence interval, DFS disease-free survival, HR haz-
ard ratio, OS overall survival. Reprinted from [16] with permission from
the American Society of Clinical Oncology. All rights reserved
Fig. 1 Hazard ratios and confidence intervals for the comparison of a
DFS and b OS with 1 year of trastuzumab versus observation after a
median follow-up of 8 years in the HERA study [14]. CI confidence
interval, DFS disease-free survival, HR hazard ratio, OS overall survival.
Reprinted from [14] with permission from Elsevier
Targ Oncol
2.3 BCIRG 006
The efficacy and safety of trastuzumab in combination with a
non-anthracycline-containing adjuvant chemotherapy regi-
men was investigated in the BCIRG 006 study (Breast
Cancer International Research Group 006). A total of 3222
women with HER2-positive early breast cancer were ran-
domized to receive AC followed by docetaxel every 3 weeks
(AC-T), AC-T plus 1 year of trastuzumab, or docetaxel and
carboplatin plus 1 year of trastuzumab (TCH).
After a median follow-up of 5.4 years, a significant DFS and
OS benefit was observed in both of the trastuzumab-containing
groups compared with the AC-T group. Five-year DFS rates
were 75 % with AC-T, 84 % with AC-T plus trastuzumab (HR
vs AC-T 0.64; p<0.001), and 81 % with TCH (HR vs AC-T
0.75; p=0.04); 5-year OS rates were 87 %, 92 % (HR vs AC-T
0.63; p<0.001), and 91 % (HR vs AC-T 0.77; p=0.04), re-
spectively [12]. No significant survival differences were found
between the two trastuzumab-containing regimens; however,
the study was not powered to detect equivalences between the
two groups. Ten-year follow-up data from the study are due to
be published in the coming months.
2.4 NOAH
The phase III NOAH study (NeOAdjuvant Herceptin) exam-
ined the benefit of trastuzumab in the neoadjuvant setting, by
comparing neoadjuvant chemotherapy (doxorubicin, paclitax-
el, cyclophosphamide, methotrexate, and fluorouracil) plus
trastuzumab followed by adjuvant trastuzumab given for a total
of 1 year with chemotherapy alone in 334 women with HER2-
positive locally advanced or inflammatory breast cancer.
Primary results, after a median follow-up of 3.2 years,
showed a significant 41 % reduction in the risk of recurrence,
progression, or death with the addition of trastuzumab (HR
0.59, 95 % CI 0.38−0.90; p=0.013), with 3-year event-free
survival (EFS) rates of 71 % in patients randomized to receive
trastuzumab plus chemotherapy versus 56% in those random-
ized to receive chemotherapy alone [13]. Corresponding
3-year OS rates were 87 % and 79 %, respectively (HR
0.62; p=0.114). The EFS benefit with trastuzumab was dem-
onstrated in all patient subgroups assessed, including those
defined by hormone receptor status or nodal status, achieve-
ment of pathologic complete response (pCR) in the breast, or
the presence or absence of inflammatory disease [13].
The survival benefit from the addition of trastuzumab to
neoadjuvant chemotherapy was sustained after a further
2 years of follow-up, with 5-year EFS rates of 58 % in the
trastuzumab group and 43% in the chemotherapy alone group
(HR 0.64, 95 % CI 0.44−0.93; p=0.016), and 5-year OS rates
of 74% and 63%, respectively (HR 0.66, 95 % CI 0.43−1.01;
p=0.055) [18]. Subgroup analyses of EFS at 5 years were
similar to those seen in the primary analysis; patients with
inflammatory disease or hormone receptor-negative tumors
gained most benefit from the addition of trastuzumab to neo-
adjuvant chemotherapy (Fig. 3) [18].
2.5 FinHer
The phase III FinHer study (Finland Herceptin) examined a
short duration of trastuzumab therapy and the effect of se-
quencing of trastuzumab prior to anthracyclines. In total,
1010 women with node-positive or high-risk node-negative
breast cancer were randomized to receive three cycles of do-
cetaxel or vinorelbine followed by three cycles of fluorouracil,
epirubicin, and cyclophosphamide (FEC). Within this group,
232 patients with HER2-positive disease were further ran-
domized to receive or not receive trastuzumab for 9 weeks
with docetaxel or vinorelbine.
Overall 3-year recurrence-free survival (RFS) rates were
higher in the docetaxel group than in the vinorelbine group, at
91.3 % and 86.4 %, respectively (HR 0.58, 95% CI 0.40−0.85;
p= 0.005). In addition, patients with HER2-positive early
breast cancer receiving trastuzumab had greater 3-year RFS
rates than those not receiving trastuzumab (89.3 % vs 77.6 %,
respectively; HR 0.42, 95 % CI 0.21−0.83; p=0.01) [19].
After a further 2 years’ follow-up, patients treated with
docetaxel had greater distant DFS than those treated with
vinorelbine overall (HR 0.66, 95 % CI 0.49−0.91;
p=0.010). Patients with HER2-positive disease treated with
trastuzumab tended to have better distant DFS than those
treated with chemotherapy alone (HR 0.65, 95 %
CI 0.38−1.12; p= 0.12), with 5-year distant DFS rates of
83.3 % and 73.0 %, respectively [20]. In exploratory analyses,
distant DFS was superior in patients who received docetaxel,
trastuzumab, and FEC compared with those who received
docetaxel and FEC (HR 0.32, 95 % CI 0.12−0.89; p=0.029)
or vinorelbine, trastuzumab, and FEC (HR 0.31, 95 %
CI 0.11−0.83; p=0.020). The authors concluded that chemo-
therapy regimens combined with fewer cycles of trastuzumab
should be explored in future studies [20].
2.6 PHARE
The French open-label noninferiority PHARE study (Protocol
for Herceptin as Adjuvant therapy with Reduced Exposure)
compared 6 months with 12 months of adjuvant trastuzumab
following completion of at least four cycles of adjuvant che-
motherapy. Overall, 1690 patients were eligible for analysis in
each arm of the study. After 3.5 years of follow-up, 175 DFS
events (10.4 %) were observed in the 12-month group com-
pared with 219 (13.0 %) in the 6-month group (2-year DFS
HR 1.28, 95 % CI 1.05−1.56; p=0.29). The study failed to
demonstrate noninferiority for the investigational arm. At the
time of the primary report the study follow-up was insufficient
to provide mature OS data [21].
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2.7 PACS04
The efficacy of 1 year of trastuzumab versus observation was
examined in 528 patients with axillary node-positive breast
cancer, following the completion of adjuvant chemotherapy,
as part of a second randomization of the phase III PACS04
(Programme Adjuvant Cancer Sein) trial.
After a median follow-up of 3.9 years, trastuzumab therapy
was associated with a non-significant reduction in the risk of
relapse versus observation (HR 0.86, 95 % CI 0.61−1.22;
p=0.41); 3-year DFS rates were 81 % and 78 %, respectively
[22]. There was no significant difference in the risk of death
between the trastuzumab arm and the observation arm
(HR 1.27, 95 % CI 0.68−2.38; p=0.41), with 3-year OS rates
of 95 % and 96 %, respectively.
3 Adjuvant Trastuzumab: Long-termCardiac Safety
Findings
Cardiac dysfunction is a known risk associated with the use of
trastuzumab, particularly when trastuzumab is given in com-
bination with anthracyclines [23]. However, unlike
anthracycline-related cardiac dysfunction, which is dose-
dependent and irreversible, t rastuzumab-induced
cardiotoxicity is independent of dose and mostly reversible
Fig. 3 Subgroup analysis of a EFS and bOS after a median follow-up of
5.4 years in the NOAH study [18].CI confidence interval, EFS event-free
survival, ER estrogen receptor,HR hazard ratio,OS overall survival, pCR
pathologic complete response, PgR progesterone receptor. Reprinted
from [18] with permission with permission from Elsevier
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following treatment discontinuation [24]. Nevertheless, recent
reports suggest that long-term cardiac damage may be
underestimated and cardiac dysfunction may not return to base-
line levels following trastuzumab withdrawal [25, 26]. Long-
term cardiac safety data, reviewed here from the pivotal adju-
vant studies of trastuzumab in HER2-positive early breast can-
cer, suggest that the incidence of cardiac adverse events (AEs)
is maintained at a relatively low level with continued follow-up.
3.1 HERA Study
Cardiac events occurring at a significantly higher incidence in
the 1-year trastuzumab group versus the observation group of
the HERA study, after a median follow-up of 1 year, were
severe congestive heart failure (CHF; 0.5 % vs 0 %, respec-
tively; p=0.002), symptomatic CHF, including severe CHF
(1.7 % vs 0.1 %, respectively; p<0.001), and left ventricular
ejection fraction (LVEF) decreases (7.1 % vs 2.2 %, respec-
tively; p<0.001) [9]. One cardiac-related death was recorded
in the observation group.
At the 8-year follow-up, cardiac disorders were reported in
1.9 % of patients in both of the trastuzumab treatment groups
(Table 1) [14]. Severely symptomatic cardiac events were rare
and occurred at a similar frequency in the 1-year and 2-year
trastuzumab groups (0.8 % and 1.0 %, respectively).
However, asymptomatic or mildly symptomatic cardiac
events, including LVEF decreases, were more frequent fol-
lowing 2 years versus 1 year of trastuzumab (7.2 % vs
4.1 %, respectively). Cardiac events were rare after comple-
tion of trastuzumab therapy [14].
3.2 NSABP B-31 and NCCTG N9831
Cardiac safety was reported separately for the NSABP B-31
and NCCTG N9831 studies. The 3-year cumulative incidence
of class III or IV CHF or cardiac-related deaths with
trastuzumab plus chemotherapy was 4.1 % in NSABP B-31
and 2.9 % in NCCTG N9831 [10]. Cumulative CHF rates
after 4 years were 3.8 % and 2.3 %, respectively [15]. Rates
of cardiac-related death after 8.4 years were 0.2 % with
trastuzumab plus chemotherapy and 0.1 %with chemotherapy
alone (Table 1) [16].
3.3 BCIRG 006
Rates of CHF and relative LVEF reduction of more than 10 %
points in the BCIRG 006 study were significantly higher in
patients receiving AC-T plus trastuzumab than in those receiv-
ing TCH after a median follow-up of 5.4 years (p<0.001)
(Table 1) [12]. Of the 194 patients (19 %) in the AC-T plus
trastuzumab group with a relative reduction in LVEF of more
than 10 %, one-third continued to experience LVEF declines
at least 4 years after randomization.
3.4 NOAH
Cardiac events occurred in 11 % of patients in each of the
trastuzumab and no trastuzumab groups at the 3.2-year
follow-up [13]. Two patients (1.7 %) experienced asymptom-
atic LVEF decline and two patients (1.7 %) developed revers-
ible class III CHF following trastuzumab therapy (Table 1).
Safety results were similar at the 5-year follow-up, with four
cardiovascular AEs considered to be drug-related (grade 2
lymphostasis and grade 2 lymphedema, each in one patient
in the trastuzumab group, and grade 2 thrombosis and grade 2
deep vein thrombosis, each in one patient in the chemotherapy
alone group) [18]. The overall incidence of CHF in the
trastuzumab group remained at 1.7 %.
3.5 FinHer
One patient (0.9 %) in the trastuzumab plus chemotherapy
group was diagnosed with symptomatic cardiac failure during
the 5 years of follow-up in the FinHer study (Table 1) [20].
The median LVEF of patients treated with trastuzumab and
chemotherapy remained at 65% throughout the 5-year follow-
up period, whereas the median LVEF decreased from 66 % to
62 % in patients receiving chemotherapy alone (p=0.006). A
similar proportion of patients in each treatment group experi-
enced a decrease in LVEF of more than 20 % points from
baseline [20].
3.6 PHARE
The PHARE study observed a significant difference in cardiac
events between the 12-month group and the 6-month group
(96 [5.7 %] vs 32 [1.9 %] patients, respectively; p<0.001).
The highest proportion of cardiac events was observed in both
study arms in patients who had received anthracycline-based
chemotherapy without a taxane [21].
3.7 PACS04
In total, 29 patients (11.2 %) in the trastuzumab arm experi-
enced either an LVEF decline of less than 45 % or an LVEF
ranging from 45 % to 50 % with a relative decrease of at least
15% after 3.9 years of follow-up in the PACS04 trial (Table 1)
[22]. Symptomatic CHF was reported in four patients (1.5 %)
in the trastuzumab arm and one patient (0.4 %) in the obser-
vation arm. No cardiac-related deaths were recorded.
4 Cardiac Safety When Adding
Other HER2-Targeted Agents
In the metastatic breast cancer setting, the addition of a second
HER2-targeted agent, pertuzumab, to trastuzumab-based
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chemotherapy did not result in any additional cardiac safety
concerns in the phase III CLEOPATRA study (CLinical
Evaluation Of Pertuzumab And TRAstuzumab) in patients
with previously untreated HER2-positive tumors. More pa-
tients in the placebo group than in the pertuzumab group ex-
perienced grade 3 or higher cardiac AEs (3.8 % vs 1.5 %,
respectively), as well as serious cardiac AEs (3.3 % vs
1.2 %, respectively) [24]. The hope is that this cardiac safety
profile will be reproduced in the ongoing phase III
APHINITY trial (Adjuvant Pertuzumab and Herceptin in
INItial TherapY of Breast Cancer), which is evaluating the
addition of pertuzumab to trastuzumab and chemotherapy in
the adjuvant setting (ClinicalTrials.gov: NCT01358877).
Long-term cardiac safety data from two pivotal phase II stud-
ies of pertuzumab in the neoadjuvant setting, TryPhaena
(ToleRabilitY of Pertuzumab, Herceptin and AnthracyclinEs
in NeoAdjuvant breast cancer; ClinicalTrials.gov:
NCT00976989) and NeoSphere (Neoadjuvant Study of
Table 1 Overview of long-term cardiac safety findings from the pivotal adjuvant studies of trastuzumab
Cardiac AEs Number (%) of patients
HERA 8 years’ follow-up [14]
1 year trastuzumab (n = 1682) 2 years trastuzumab (n= 1673) Observation (n=1744)
Grade 3/4 cardiac disorders 32 (1.9) 32 (1.9) 8 (0.5)
Severely symptomatic cardiac events* 14 (0.8) 16 (1.0) 2 (0.1)
Asymptomatic cardiac events† 69 (4.1) 120 (7.2) 15 (0.9)
NSABP B-31 and NCCTG N9831 8.4 years’ follow-up [16]
Trastuzumab+ chemotherapy (n=2028) Chemotherapy alone (n = 2018)
CHF 2 (0.1) 3 (0.1)
Cardiac arrest 1 (<0.1) 3 (0.1)
Cardiomyopathy 0 1 (<0.1)
Myocardial infarction 0 1 (<0.1)
Unspecified cardiac condition 0 1 (<0.1)
BCIRG 006 5.4 years’ follow-up [12]
AC-T (n = 1073) AC-T + trastuzumab (n=1074) TCH (n = 1075)
Cardiac-related death 0 0 0
Class III/IV CHF 7 (0.7) (n = 1018) 21 (2.0) (n = 1042) 4 (0.4)‡ (n = 1031)
LVEF relative decrease >10 % 114 (11.2)§ 194 (18.6) 97 (9.4)‡
NOAH 3.2 years’ follow-up [13]
Trastuzumab + chemotherapy (n=115) Chemotherapy alone (n = 113)
Grade 3/4 left ventricular dysfunction 2 (1.7) 0
LVEF decrease ≥20 % points from baseline 2 (1.7) 1 (0.9)
Class III CHF 2 (1.7) 0
FinHer 5 years’ follow-up [20]
Trastuzumab + chemotherapy (n=115) Chemotherapy alone (n = 116)
LVEF decrease >20 % points from baseline 7 (6.8) 10 (10.5)
Symptomatic heart failure 1 (0.9) 2 (1.7)
Myocardial infarction 0 0
PHARE 3.5 years’ follow-up [21]
12-month group (n = 1690) 6-month group (n = 1690)
LVEF <50 % 106 (6.3) 79 (4.7)
LVEF <50 % independent of baseline and a decrease of >10 % 81 (4.8) 60 (3.6)
PACS04 3.9 years’ follow-up [22]
1 year trastuzumab (n = 260) Observation (n = 268)
Symptomatic CHF 4 (1.5) 1 (0.4)
LVEF decline <45 or 45−50 % with relative decrease ≥15 % 29 (11.2) 7 (2.6)
AC-T doxorubicin and cyclophosphamide followed by docetaxel, AE adverse event, CHF congestive heart failure, LVEF left ventricular ejection
fraction, NYHA New York Heart Association, TCH docetaxel and carboplatin plus trastuzumab
*NYHA class III or IVand a significant LVEF drop ≥10 % points from baseline and to an absolute LVEF <50 %, or cardiac death
†NYHA class I or II with a significant LVEF drop ≥10 % points from baseline and to an absolute LVEF <50 % confirmed by repeat assessment
‡ p< 0.001 for the comparison of the AC-T plus trastuzumab group versus the TCH group
§ p< 0.001 for the comparison of the AC-T plus trastuzumab group versus the AC-T group
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Pertuzumab and Herceptin in an Early Regimen Evaluation;
Clinical Trials.gov: NCT00545688), are also eagerly awaited.
Despite these encouraging cardiac safety findings, patients
receiving trastuzumab or pertuzumab should be routinely
monitored for left ventricular function prior to and during
treatment to detect early cardiotoxicity. Echocardiograms are
widely considered the gold standard monitoring method since
they are safe, cost-effective, and readily available, but experi-
enced operators are required as the potential for variability is
high. There is some debate as to the optimal LVEF monitor-
ing interval. The US Food and Drug Administration recom-
mends monitoring at baseline and at every 3 months during
and upon completion of trastuzumab [27]. The UK National
Cancer Research Institute suggests monitoring at baseline
and at 4 and 8 months during trastuzumab; further assess-
ment is only recommended if cardiovascular intervention
has been required [28]. More recently, the European
Society for Medical Oncology clinical practice guidelines
suggested cardiac monitoring at baseline, at 3, 6, and
9 months during trastuzumab, and at 12 and 18 months after
treatment initiation [29].
5 Adjuvant Trastuzumab: Long-term Non-cardiac
Safety Data
Table 2 provides an overview of non-cardiac grade 3/4 AEs
observed across the pivotal adjuvant studies. Overall, there
were few differences in toxicities recorded with the exception
of the BCIRG 006 study, in which there was an increased rate
of acute leukemia in the anthracycline-containing arms versus
the non-anthracycline arm [12]. Seven patients in the
anthracycline-containing groups developed acute leukemia,
as well as one patient in the TCH group who received an
anthracycline outside of the study for lymphoma. Five of these
patients died as a result of their leukemia.
Much of the non-cardiac toxicity described in the adjuvant
studies was attributable to the chemotherapy backbone rather
than the trastuzumab antibody. Allergic reaction was reported
in 5.8 % of patients treated with docetaxel plus trastuzumab in
the FinHer study, but in 0 % of patients treated with vinorel-
bine plus trastuzumab [19]. Diarrhea was reported more fre-
quently in the chemotherapy-alone arm of the NOAH study
than in the trastuzumab plus chemotherapy arm (3.5 % vs
0.9 %, respectively) [13]. Data on the effects of long-term
trastuzumab use and weight gain or dermatologic conditions
were scarce in these pivotal trials.
6 Future Outlook
Data from a number of ongoing or planned randomized phase
II/III trials will help to elucidate the role of newer HER2-
targeted agents in early breast cancer. The phase II ATEMPT
trial is comparing the antibody–drug conjugate trastuzumab
emtansine with paclitaxel plus trastuzumab after adjuvant
anthracycline-based chemotherapy in patients with resected
stage I disease (ClinicalTrials.gov: NCT01853748). The effi-
cacy and safety of trastuzumab emtansine versus trastuzumab
as adjuvant therapy will be assessed in the phase III
KATHERINE study in patients with residual invasive disease
in the breast or axillary lymph nodes following neoadjuvant
trastuzumab-containing therapy (ClinicalTrials.gov:
NCT01772472). An additional phase III study, KAITLIN,
will evaluate the safety and efficacy of a taxane-based therapy
with either trastuzumab and pertuzumab, or trastuzumab
emtansine and pertuzumab in the adjuvant setting and follow-
ing an anthracycline-based regimen (ClinicalTrials.gov:
NCT01966471). A phase III study, KRISTINE, will evaluate
the safety and efficacy of neoadjuvant trastuzumab emtansine
with pertuzumab compared with chemotherapy combined
with trastuzumab and pertuzumab for patients with HER2-
positive breast cancer (ClinicalTrials.gov: NCT02131064).
The recently developed SC formulation of trastuzumab ad-
ministered once every 3 weeks for 1 year is approved globally
as (neo)adjuvant treatment for HER2-positive early breast
cancer. The approval was based on the results of the random-
ized phase III HannaH study (enHANced treatment with
NeoAdjuvant Herceptin), in which the SC formulation of
trastuzumab was noninferior in efficacy to intravenous (IV)
administration of trastuzumab, with a similar safety profile
[30]. The incidence of grade 3 or higher AEs was comparable
with SC and IV administration of trastuzumab (53.5 % vs
52.3 %, respectively) after a median follow-up of 20 months
[31]; the majority of these were hematologic toxic effects,
most commonly neutropenia, leukopenia, and febrile neutro-
penia [30]. EFS rates at 3 years post-randomization were 76%
and 73 % with SC and IV administration of trastuzumab, re-
spectively [31]. In both treatment arms, pCR was associated
with improved long-term EFS: 3-year EFS rates were 19 %
higher in patients who achieved pCR versus those who did not
[32]. The overall safety profile of SC administration of
trastuzumab in HannaH was consistent with the established
safety profile of IVadministration of trastuzumab. Safety find-
ings were similar with SC administration of trastuzumab in the
phase II adjuvant PrefHer study (Preference for Herceptin SC
or IV administration), which assessed patient preference for
SC or IV administration [33, 34]. At the primary analysis,
88.9 % (415/467) of patients preferred SC administration of
trastuzumab (p<0.0001, two-sided test against the null hy-
pothesis of 65 % SC preference), 9.6 % (45/467) preferred
IV administration, and 1.5 % (7/467) had no preference, with
time saving (80.3 %) and less pain/discomfort/side effects
(34.3 %) being the main reasons for patients’ preferences
[34]. Interim results from the phase III SafeHer study
(Safety of assisted- and self-administered subcutaneous
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Herceptin) confirmed the safety of SC administration of
trastuzumab via hand-held syringe as adjuvant therapy in
combination with chemotherapy for HER2-positive early
breast cancer [35]. No new safety signals were identified
Table 2 Overview of long-term safety data from the pivotal adjuvant studies of trastuzumab
Grade 3/4 AEs, by body system or term Number (%) of patients
HERA 8 years’ follow-up [14]
1 year trastuzumab (n= 1682) 2 years trastuzumab (n= 1673) Observation (n= 1744)
At least one grade 3/4 AE 275 (16.3) 342 (20.4) 143 (8.2)
Neoplasms 60 (3.6) 77 (4.6) 31 (1.8)
Infections/infestations 37 (2.2) 55 (3.3) 12 (0.7)
Nervous system disorders 14 (0.8) 33 (2.0) 12 (0.7)
Vascular disorders 31 (1.8) 33 (2.0) 17 (1.0)
Musculoskeletal disorders 25 (1.5) 28 (1.7) 22 (1.3)
General disorders/administration site conditions 17 (1.0) 27 (1.6) 8 (0.5)
Gastrointestinal disorders 17 (1.0) 28 (1.7) 6 (0.3)
Injury/poisoning/procedural complications 18 (1.1) 23 (1.4) 12 (0.7)
BCIRG 006 5.4 years’ follow-up* [12]
AC-T (n= 1050) AC-T + trastuzumab (n= 1068) TCH (n= 1056)
Arthralgia 34 (3.2) 35 (3.3) 15 (1.4)
Myalgia 55 (5.2) 56 (5.2) 19 (1.8)
Hand-foot syndrome 20 (1.9) 20 (1.9) 0
Stomatitis 37 (3.5) 31 (2.9) 15 (1.4)
Vomiting 65 (6.2) 72 (6.7) 37 (3.5)
Neutropenia 665 (63.3) 764 (71.5) 696 (65.9)
Leukopenia 544 (51.8) 644 (60.3) 509 (48.2)
Anemia 25 (2.4) 33 (3.1) 61 (5.8)
Thrombocytopenia 17 (1.6) 22 (2.1) 64 (6.1)
NOAH 3.2 years’ follow-up [13]
Trastuzumab + chemotherapy (n= 115) Chemotherapy alone (n = 113)
Febrile neutropenia 2 (1.7) 2 (1.8)
Neutropenia 3 (2.6) 5 (4.4)
Diarrhea 1 (0.9) 4 (3.5)
Stomatitis 1 (0.9) 4 (3.5)
Pneumonia 1 (0.9) 0
Arthralgia 0 3 (2.7)
Myalgia 1 (0.9) 1 (0.9)
Peripheral neuropathy 1 (0.9) 2 (1.8)
FinHer 3 years’ follow-up [19]
Docetaxel + trastuzumab (n = 54) Vinorelbine + trastuzumab (n= 61)
Neutropenia 54 (100) 34 (55.7)
Elevated AST 0 2 (3.3)
Stomatitis 2 (4.0) 0
Allergic reaction 3 (5.8) 0
Infection 3 (5.9) 1 (1.6)
Neutropenic fever 16 (29.6) 3 (4.9)
Motor neuropathy 0 1 (1.6)
Fatigue 4 (8.0) 3 (4.9)
AC-T doxorubicin and cyclophosphamide followed by docetaxel,AE adverse event, ASTaspartate aminotransferase, TCH docetaxel and carboplatin plus
trastuzumab
*Showing only AEs at p< 0.05 for the comparison of the AC-T plus trastuzumab group versus the TCH group
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and results were consistent with the known safety profile of
adjuvant trastuzumab. The SC formulation of trastuzumab has
now been widely adopted.
7 Discussion
The optimal duration of adjuvant trastuzumab treatment has
been debated since the selection of the 1-year time scale based
on pivotal trial results [36]. Recent data from the HERA study
confirm that 2 years of trastuzumab following adjuvant che-
motherapy is not more effective than 1 year [14]. Several
ongoing or recently completed phase III trials address whether
a shorter than 1-year course of trastuzumab might be suffi-
cient. After 3.5 years of follow-up, the PHARE study failed
to show noninferiority of 6 months versus 12 months of adju-
vant administration of trastuzumab [21]. Similarly, the
Hellenic Oncology Group study failed to demonstrate nonin-
feriority for 6 months of adjuvant trastuzumab (in combina-
tion with dose-dense docetaxel following FEC) versus
12 months of treatment [37]. Results of the ongoing random-
ized PERSEPHONE trial comparing 6monthswith 12months
of adjuvant trastuzumab (ClinicalTrials.gov: NCT00712140)
and the recently completed Synergism Or Long Duration
(SOLD) trial, comparing 9 weeks with 12 months of adjuvant
trastuzumab (ClinicalTrials.gov: NCT00593697), are eagerly
awaited [38]. At this present time, 1 year of trastuzumab treat-
ment remains the standard of care in HER2-positive early
breast cancer.
An observational study assessing the real-life use of adju-
vant trastuzumab in 1245 patients with HER2-positive breast
cancer reported a relapse rate of 10.9% in trastuzumab-treated
patients versus 22.6% in untreated patients (median follow-up
37.4 and 62.1 months, respectively), with lower DFS in re-
lapsed versus non-relapsed patients [39]. The relapse rate at
5 years was 17 %, which is in line with the BCIRG 006 study
and other observational studies, but much lower than that re-
ported in the HERA study [39].
Numerous studies, including combined results from the
NSABP B-31 and NCCTGN9831 trials, have identified older
age as a risk factor for trastuzumab-induced cardiotoxicity
[40–44]. In addition, in a large cohort of patients with early
breast cancer, older patients (age 80 years or more) had less
chance of completing adjuvant trastuzumab than younger pa-
tients (66–70 years; odds ratio 0.40, 95 % CI 0.30−0.55) [45].
Those who failed to complete the planned treatment experi-
enced significantly higher rates of hospitalizations due to car-
diac AEs than those who completed treatment (8.1 % vs
2.6 %; p<0.001). Older age was also a poor prognostic factor
for RFS in patients with HER2-positive early breast cancer
receiving 1 year of trastuzumab (age at least 70 years; relative
risk 2.7, 95 % CI 1.19−6.13; p=0.017) [46]. Future adjuvant
breast cancer treatment strategies should focus on reducing
cardiotoxicity and improving efficacy in elderly patients re-
ceiving trastuzumab [47].
Reducing cardiac events and preventing cardiac toxicity is
a key goal in developing adjuvant treatment strategies for
patients with HER2-positive breast cancer. The discovery of
biomarkers or echocardiographic changes that could predict
cardiac deterioration in trastuzumab-treated patients, or detect
patients with the greatest chance of LVEF recovery following
trastuzumab withdrawal, would be highly beneficial. A pre-
dictive role of troponins and B-type natriuretic peptides in the
development of cardiac failure post-chemotherapy has been
indicated in a number of publications [48]. Moreover, highly
sensitive troponin T and cardiac diastolic function were pre-
dictive of cardiotoxicity in patients with breast cancer receiv-
ing adjuvant trastuzumab [49], while troponin I was an inde-
pendent predictor of trastuzumab-induced cardiotoxicity and
lack of LVEF recovery [50].
In patients with relatively small cancers, or otherwise de-
fined as low risk of recurrence, the addition of trastuzumab
may be of only limited benefit. Here the potential cardiac side
effects of trastuzumab should be considered and may dissuade
its use [47]. Exploratory subgroup analyses from the NCCTG
N9831 study suggest that patients with high levels of stromal
tumor-infiltrating lymphocytes (at least 60 % of cells in the
section) do not derive benefit from the addition of trastuzumab
to chemotherapy, with estimated 10-year RFS rates of 90.9 %
with chemotherapy and 80.0 % with trastuzumab plus chemo-
therapy (p=0.22) [51]. While these data might suggest that
such patients may not require trastuzumab treatment, they are
hypothesis-generating and more extensive research is needed
before they can be used to influence clinical decision-making.
Limiting the amount of chemotherapy administered in combi-
nation with trastuzumab has also been investigated as a means
of reducing the side effect burden in patients with low-risk
disease. The APT trial enrolled patients with node-negative,
small HER2-positive tumors (less than 3 cm) to receive adju-
vant paclitaxel plus trastuzumab, followed by trastuzumab
monotherapy. After 3 years of follow-up, the risk of invasive
recurrence was just 1.3 %. In this good prognosis subgroup,
6 % of patients withdrew as a result of AEs; symptomatic
CHF occurred in 0.5 % of patients, but LVEF normalized after
trastuzumab discontinuation [52]. These results demonstrate
the efficacy and safety of this less intensive regimen in a low-
risk patient group often under-represented in adjuvant
trastuzumab trials.
A large body of evidence is lacking for the combination of
hormones and trastuzumab without chemotherapy in the ad-
juvant setting.
LVEF is the most commonly usedmarker of left ventricular
systolic function and provides thresholds for intervention for
patients with cardiovascular disease. The value can be derived
from imaging modalities but two-dimensional (2D) transtho-
racic echocardiography is the most widely used as it is safe
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and cost-effective, especially for patients requiring serial
scans. The main drawback is interobserver variability, but this
is low with experienced operators. Three-dimensional echo-
cardiography holds great promise for the future as the repro-
ducibility is superior to 2D, but the service is currently limited
to a few centers. For patients with poor acoustic windows, IV
contrast agents improve endocardial border definition. Studies
are also focusing on the role of speckle tracking, which can be
performed off-line from conventional 2D echo scans and pro-
vides information on myocardial deformation in the long, ra-
dial, and circumferential axes. This allows the detection of
subclinical cardiac dysfunction before LVEF has reduced.
Speckle tracking has provided insights into many disease pro-
cesses but as yet has no role in the clinical setting.
Most data regarding mechanisms of cardiotoxicity due
to cancer therapy have been obtained from animal models.
Further studies to improve our understanding of the rele-
vance of these pathways in humans are necessary for drug
therapies to be developed. Drugs that promote increased
cardiac reserve and reverse remodeling under the stress of
cancer therapy are routinely used as cardioprotective mea-
sures to continue and complete therapy. These include
certain beta blockers, angiotensin-converting enzyme in-
hibitors, and aldosterone receptor antagonists. Currently,
data only exist to support use of these drugs when there is
a clear reduction in LVEF rather than with subclinical left
ventricular dysfunction. Omission of anthracycline thera-
py to avoid pre-trastuzumab damage is another strategy
used in some high cardiac risk individuals.
8 Conclusion
Data reviewed within this paper confirm the significant sur-
vival benefit afforded by the addition of trastuzumab to che-
motherapy in patients with HER2-positive early breast cancer,
and the acceptable safety profile of this treatment. Long-term
cardiac safety data also suggest that the incidence of cardiac
AEs is maintained at a relatively low level with continued
follow-up. Several ongoing adjuvant trials will define the role
of newer HER2-targeted agents in early breast cancer.
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